Integra LifeSciences Creates CTO Role to Accelerate Innovation
Event summary
- Integra LifeSciences created a new Chief Technology Officer (CTO) role, appointing Teshtar Elavia to lead R&D and product development.
- Michael Hutchinson was appointed as Executive Vice President, Chief Legal Officer, and Secretary to oversee global legal, compliance, and ESG functions.
- Kerri DiPietro was named Corporate Vice President and Chief Quality Officer to strengthen global quality management systems.
- Elavia brings over 20 years of experience in R&D from companies like Becton Dickinson, Eli Lilly, Medtronic, and Johnson & Johnson.
- Hutchinson and DiPietro have extensive backgrounds in legal, compliance, and quality roles at firms including LivaNova, Stryker, and Boston Scientific.
The big picture
Integra LifeSciences is doubling down on innovation and operational excellence by restructuring its executive leadership. The creation of a CTO role signals a strategic shift toward accelerating product development, while the appointments of Hutchinson and DiPietro underscore a focus on legal, compliance, and quality management. These moves come as the medical technology sector faces increasing pressure to balance innovation with regulatory scrutiny and ESG commitments.
What we're watching
- Innovation Pipeline
- How the new CTO will accelerate product development and strengthen Integra’s innovation pipeline through organic and partnership efforts.
- Regulatory Compliance
- Whether Kerri DiPietro’s focus on global quality management will enhance regulatory compliance and post-market surveillance.
- ESG Integration
- The pace at which Michael Hutchinson integrates ESG functions into Integra’s global operations and governance.